[1]叶海琼,秦明丽,傅晓冬*.卵巢癌程序性细胞凋亡因子4的临床意义及对预后的评估[J].中国计划生育和妇产科,2018,(4):58-61.
　YE Hai-qiong,QIN Ming-li,FU Xiao-dong*.Clinical significance and prognostic value of programmed cell death factor 4 in patients with ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(4):58-61.
点击复制

卵巢癌程序性细胞凋亡因子4的临床意义及对预后的评估
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2018年4期
页码:
58-61
栏目:
论著与临床
出版日期:
2018-04-25

文章信息/Info

Title:
Clinical significance and prognostic value of programmed cell death factor 4 in patients with ovarian cancer
作者:
叶海琼; 秦明丽; 傅晓冬*
西南医科大学附属医院妇产科
Author(s):
YE Hai-qiong; QIN Ming-li; FU Xiao-dong*
Department of Obstetrics and Gynecology, Affiliated Hospital of Southwest Medical University,Luzhou Sichuan 646000,P.R.China
关键词:
卵巢癌; 程序性细胞凋亡因子4; 生存率; 免疫组化
Keywords:
ovarian cancer;  programmed cell death factor 4;  survival rate;  immunohistochemistry
分类号:
R 73731
摘要:
目的探讨卵巢癌患者程序性细胞凋亡因子4（programmed cell death factor 4，PDCD 4）检测的临床意义及对疾病的预后评估。方法选取2013年1月至2015年1月在西南医科大学附属医院妇产科行卵巢癌手术的癌组织标本67例，并和距离癌组织边缘2 cm以上的正常卵巢组织18例为对照，免疫组化法检测卵巢癌组织和正常卵巢组织的PDCD 4蛋白的表达差异，探讨PDCD 4蛋白表达量和临床病理特征之间的相关性，并通过Log-rank检验比较PDCD 4蛋白高表达和低表达患者之间的生存差别。结果67例卵巢癌组织样本中，2836 %表现为PDCD 4高表达，7164 %低表达，卵巢癌组织中PDCD 4的高表达率明显高于正常卵巢组织（P<005）。年龄、FIGO分期、发病部位对PDCD 4蛋白的表达均无显著影响（P>005），而癌组织的分化程度显著影响PDCD 4蛋白的表达（P<005）。患者年龄、发病部位、分化程度对卵巢癌患者术后2年生存率无明显影响（P>005)，而FIGO分期和PDCD 4蛋白的表达量则显著影响患者2年生存率（P<005）。PDCD 4蛋白高表达的卵巢癌患者的2年生存率为6842 %，PDCD 4蛋白低表达组为3750 %，两组患者2年生存率差异有统计学意义（P<005）。结论PDCD 4作为卵巢癌组织中的一种抑癌基因，可能对卵巢癌的早期诊断具有一定的意义，PDCD 4蛋白的表达水平可能对卵巢癌患者的预后评估存在一定的价值。
Abstract:
ObjectiveTo investigate the clinical significance and prognostic value of programmed cell death factor 4 (PDCD 4) detection in patients with ovarian cancer. Methods67 cases of cancer tissue samples from ovarian cancer operated in Affiliated Hospital of So

参考文献/References:

［1］杨念念，严亚琼，郑荣寿，等．中国2009年卵巢癌发病与死亡分析 ［J］．中国肿瘤，2013，22（8）：617-621． ［2］张爽爽，夏庆民，郑荣寿，等．中国2010年卵巢癌发病与死亡分析 ［J］．中国肿瘤，2016，25（3）：169-173． ［3］HUANG Bao-hua, CHEN Lei, BAO Cui-xia, et al The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis［J］. Onco Targets Ther, 2015, 8: 2617-2625. ［4］Riester M, WEI W, Culhane AC, et al. Abstract 2355:risk prediction for late-stage ovarian cancer by meta-analysis of 1,525 patient samples ［J］. Cancer Res, 2014, 74(5): 2504-2511. ［5］李娅，佟秀琴．C-erbB 2与PDCD 4在卵巢癌中的研究进展 ［J］．中华临床医师杂志（电子版），2013，7（15）：7183-7185． ［6］YU Han, ZENG Jiping, LIANG Xiuming, et al. Helicobacter pylori promotes epithelial-mesenchymal transition in gastric cancer by downregulating programmed cell death protein 4 (PDCD4)［J］. PLoS One, 2014, 9(8): e105306. ［7］WANG Yuquan, GUO Rende, GUO Ruimeng, et al. MicroRNA182 promotes cell growth, invasion and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas ［J］. J Cell Biochem, 2013, 114(7): 1464-1473. ［8］李霞，裴艳丽．程序性细胞死亡因子4与细胞色素C在上皮性卵巢癌中的表达及其关系 ［J］．中国医药导报，2015，12（15）：107-108，112． ［9］Cho HY, Kim K, Kim YB, et al. Expression patterns of Nrf2 and Keap1 in ovarian cancer cells and their prognostic role in disease recurrence and patient survival［J］. International Journal of Gynecological Cancer, 2017, 27(3): 412-419. ［10］LI Tian-ren, Xue H, GUO Yi, et al. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer ［J］. Oncol Rep, 2014, 31(4): 1825-1831. ［11］Stone RL, Nick AM, Mcneish IA, et al. Paraneoplastic thrombocytosis in ovarian cancer ［J］. N Engl J Med, 2012, 366(7): 610-618. ［12］万冬，杨廷桐，秦玉凤，等．miRNA 21/PDCD 4环路在卵巢癌组织中的表达 ［J］．肿瘤防治研究，2013，40 （9）：869-872． ［13］Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial［J］. Lancet Oncol, 2014, 15(8): 852-861. ［14］Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized prostate,lung,colorectal,and ovarian cancer screening trial:mortality results after 13 years of follow-up［J］. Journal of the National Cancer Institute, 2012, 104(10): 793-794. ［15］LI Xiancheng, XIN Shiyong, HE Zhongzhou, et al. MicroRNA21 (miR21) Post-Transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma ［J］. Cellular Physiology and Biochemistry, 2014, 33(6): 1631-1642. ［16］WEI Zeng-tao, ZHANG Xia, WANG Xiao-yan, et al. PDCD4 inhibits the malignant phenotype of ovarian cancer cells［J］. Cancer Sci, 2009, 100(8): 1408-1413.

相似文献/References:

[1]伍军平,陈宝霞,罗新,等.妊娠晚期胎死宫内合并卵巢癌破裂1例[J].中国计划生育和妇产科,2011,(03):0.
[2]张爱臣,佟玲玲.卵巢癌的诊治进展[J].中国计划生育和妇产科,2013,(01):0.
　ZHANG Ai-chen,TONG Ling-ling.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(4):0.
[3]李慧,汤小晗,卢美松*.肝素结合表皮生长因子与卵巢癌顺铂化疗耐药性关系的研究[J].中国计划生育和妇产科,2016,(12):15.
　LI Hui,TANG Xiao-han,LU Mei-song*.Study on relationship between HB-EGF and resistance of ovarian cancer to chemotherapy drug[J].Chinese Journal of Family Planning & Gynecotokology,2016,(4):15.
[4]何丽,林永红,李笑晓,等.防己诺林碱联用紫杉醇对耐药卵巢癌SKOV3/ADM细胞作用机制的初步研究[J].中国计划生育和妇产科,2017,(6):59.
　HE Li,LIN Yong-hong,LI Xiao-xiao,et al.Effect of fangchinoline combined with paclitaxel on drug resistant ovarian cancer SKOV3 / ADM cells: a preliminary study[J].Chinese Journal of Family Planning & Gynecotokology,2017,(4):59.
[5]卢丹华,洪莉*,杨将,等.Jagged1-STAT 3信号轴对卵巢癌细胞A 2780迁移能力的影响[J].中国计划生育和妇产科,2017,(8):72.
　LU Dan-hua,HONG Li*,YANG Jiang,et al.Effect of Jagged1-STAT 3 signal axis on migration ability of ovarian cancer cell A 2780[J].Chinese Journal of Family Planning & Gynecotokology,2017,(4):72.
[6]张雪梅.紫杉醇联合洛铂化疗方案对晚期初治卵巢癌术后 患者早期临床疗效及毒副反应发生率的分析[J].中国计划生育和妇产科,2018,(2):72.
　ZHANG Xue-mei.Early clinical efficacy and side effects of paclitaxel combined with lobaplatin regimen on postoperative patients with advanced ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(4):72.
[7]石亚利,梁华茂*,姚颖.腹腔镜卵巢恶性肿瘤再分期手术临床分析（附38例报道）[J].中国计划生育和妇产科,2018,(3):37.
　SHI Ya-li,LIANG Hua-mao*,YAO Ying.Clinical analysis of laparoscopic restaging surgery for ovarian malignancies (report of 38 cases)[J].Chinese Journal of Family Planning & Gynecotokology,2018,(4):37.
[8]陈彩香*,文锦娣,杨海珍.子宫内膜异位症相关卵巢癌患者临床特点分析[J].中国计划生育和妇产科,2018,(4):62.
　CHEN Cai-xiang*,WEN Jin-di,YANG Hai-zhen.Clinical characteristics of patients with endometriosis associated ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(4):62.
[9]范云龙,杨建华.微生物在卵巢癌发病机制与治疗中的作用[J].中国计划生育和妇产科,2018,(5):24.
[10]吴亚男,李红霞*,孟宪宁,等.子宫内膜异位症及卵巢癌患者血清脑源性神经营养因子水平的表达及意义[J].中国计划生育和妇产科,2018,(9):32.
　WU Ya-nan,LI Hong-xia*,MENG Xian-ning,et al.Expression and significance of serum BDNF in patients with endometriosis and ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(4):32.

更新日期/Last Update: 2018-04-25